Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI (TAILORED-CHIP)

This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance

percutaneous coronary intervention
aspirin
diabetes
  • 7 views
  • 28 Feb, 2022
  • 14 locations
Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions

expert consensus, the investigators chose aspirin + Ticagrelor/Clopidogrel for 3-month followed by Ticagrelor/Clopidogrel monotherapy for 3-month to be the antiplatelet regimen in DCB arm. In contrast to

coronary angioplasty
chromium
infarct
revascularisation
myocardial infarction
  • 0 views
  • 30 Jun, 2021
  • 1 location
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

). In the OPTIMA-4 sub-study, 1472 subjects who prefer dabigatran will be randomly assigned in a 1:1 ratio to a dual antithrombotic therapy of dabigatran 110 mg twice daily with ticagrelor 90 mg

infarct
myocardial infarction
thrombosis
ticagrelor
aspirin
  • 51 views
  • 03 May, 2022
  • 1 location
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial (HOST-IDEA)

We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems still needs to be established. With a 2x2 factorial design for patients of stable angina or silent ischemia, the investigators …

coronary artery stenosis
ischemia
infarct
stable angina
myocardial infarction
  • 0 views
  • 26 Jan, 2022
  • 4 locations
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials

Prospective, multicenter, randomized, double-blind, placebo-controlled trials.

infarct
myocardial infarction
troponin
dapt
stenosis
  • 0 views
  • 18 Nov, 2021
  • 1 location
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA)

The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).

prasugrel
clopidogrel
ticagrelor
antiplatelet therapy
acute coronary syndrome
  • 0 views
  • 30 May, 2022
  • 10 locations
Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES (PARTHENOPE)

New-generation metallic drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention (PCI). Currently, few data are available as regards to the safety and efficacy of the Cre8 amphilimus-eluting stent (Cre8 AES, Alvimedica, Instanbul, Turkey) in comparison with the biodegradable polymer everolimus-eluting stent (Synergy EES, Boston Scientific, …

arterial disease
biodegradable polymer
dapt
percutaneous coronary intervention
antiplatelet therapy
  • 11 views
  • 21 Feb, 2022
  • 12 locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PACES)

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

dabigatran
ticagrelor
vitamin k
aspirin
antiplatelet therapy
  • 112 views
  • 27 Apr, 2022
  • 43 locations
CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4 (SMART-CHOICE4)

This study is multi-center, open label, two-by-two factorial, randomized, noninferiority trial to compare the efficacy and safety of polymer-free cobalt-chromium thin drug-coated stents (BioFreedom Ultra) with biodegradable polymer ultrathin sirolimus-eluting stents (Orsiro Mission) and prasugrel monotherapy after 1-month dual antiplatelet therapy (DAPT) of aspirin plus prasugrel with 12-month DAPT of …

  • 0 views
  • 25 May, 2022
  • 1 location
CES1 Crossover Trial of Clopidogrel and Ticagrelor

aggregometry, in healthy participants treated with clopidogrel and ticagrelor. We hypothesize that genetic variation in CES1 will significantly impact on-clopidogrel platelet aggregation while having a minimal

Accepts healthy volunteers
clopidogrel
genetic variation
ticagrelor
platelet aggregation
  • 68 views
  • 24 Mar, 2022
  • 1 location